Literature DB >> 6692040

A novel phospholipid in irreversibly sickled cells: evidence for in vivo peroxidative membrane damage in sickle cell disease.

S K Jain, S B Shohet.   

Abstract

In individuals with sickle cell disease, a variable number of irreversibly sickled cells (ISC) is present that may contribute to the pathophysiology of sickle cell anemia. The present study was undertaken to determine the possible role of membrane lipid peroxidation in the genesis of ISC. After 24 hr of simple aerobic incubation, sickle cells accumulated 2-3 times more malonyldialdehyde (MDA), an end product of lipid peroxidation, than normal cells. To assess the possibility of peroxidative damage in ISC in vivo, ISC were separated from sickle blood using Stractan density gradients. Lipid extracts of the untreated ISC-enriched fraction of sickle blood showed significant fluorescence and contained a novel phospholipid:MDA adduct that was not seen in control cells. Taken together, these observations suggest that ISC have previously undergone lipid peroxidative damage and the accumulation of MDA in vivo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6692040

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.

Authors:  Patrick B Walter; Ellen B Fung; David W Killilea; Qing Jiang; Mark Hudes; Jacqueline Madden; John Porter; Patricia Evans; Elliott Vichinsky; Paul Harmatz
Journal:  Br J Haematol       Date:  2006-10       Impact factor: 6.998

2.  Preparation of Schiff base adducts of phosphatidylcholine core aldehydes and aminophospholipids, amino acids, and myoglobin.

Authors:  A Ravandi; A Kuksis; N Shaikh; G Jackowski
Journal:  Lipids       Date:  1997-09       Impact factor: 1.880

3.  Band 3 and glycophorin are progressively aggregated in density-fractionated sickle and normal red blood cells. Evidence from rotational and lateral mobility studies.

Authors:  J D Corbett; D E Golan
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

4.  Effects of a single sickling event on the mechanical fragility of sickle cell trait erythrocytes.

Authors:  Tennille D Presley; Andreas S Perlegas; Lauren E Bain; Samir K Ballas; James S Nichols; Hernan Sabio; Mark T Gladwin; Gregory J Kato; Daniel B Kim-Shapiro
Journal:  Hemoglobin       Date:  2010       Impact factor: 0.849

Review 5.  The proteome of sickle cell disease: insights from exploratory proteomic profiling.

Authors:  Susan Yuditskaya; Anthony F Suffredini; Gregory J Kato
Journal:  Expert Rev Proteomics       Date:  2010-12       Impact factor: 3.940

6.  Hydroxyurea-induced expression of glutathione peroxidase 1 in red blood cells of individuals with sickle cell anemia.

Authors:  Chun-Seok Cho; Gregory J Kato; Seung Ha Yang; Sung Won Bae; Jong Seo Lee; Mark T Gladwin; Sue Goo Rhee
Journal:  Antioxid Redox Signal       Date:  2010-07-01       Impact factor: 8.401

7.  In vivo externalization of phosphatidylserine and phosphatidylethanolamine in the membrane bilayer and hypercoagulability by the lipid peroxidation of erythrocytes in rats.

Authors:  S K Jain
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

8.  Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease.

Authors:  Alex George; Suvarnamala Pushkaran; Diamantis G Konstantinidis; Sebastian Koochaki; Punam Malik; Narla Mohandas; Yi Zheng; Clinton H Joiner; Theodosia A Kalfa
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

9.  Sickle cell membranes and oxidative damage.

Authors:  C Rice-Evans; S C Omorphos; E Baysal
Journal:  Biochem J       Date:  1986-07-01       Impact factor: 3.857

10.  Abnormal redox status of membrane-protein thiols in sickle erythrocytes.

Authors:  B H Rank; J Carlsson; R P Hebbel
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.